Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. · 2016
Read Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. by Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4713865.txt.
Description
Matthew J. Armstrong, Diana Hull, Kathy Guo, and eight colleagues tested the diabetes drug liraglutide in fatty liver disease, in the Journal of Hepatology in 2016. Non-alcoholic steatohepatitis, or NASH, inflames and scars the liver and lacks safe drug treatments. Insulin resistance in fat tissue floods the liver with toxic fat breakdown products. Inside a placebo-controlled trial, fourteen patients with biopsy-proven NASH received liraglutide or placebo for twelve weeks, with detailed metabolic measurements before and after.
The drug group lost weight and waist size while placebo patients did not change. Liver enzymes and inflammation markers improved, fat tissue worked better, and the liver's own insulin response strengthened, though muscle response did not. Cell studies pointed to direct fat-lowering effects in liver cells. The authors read the pattern as reduced lipotoxicity, the fat-driven injury at NASH's core, supporting larger trials of this drug class.
Catalog record
| CREATOR | Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |